Daratumumab, Pomalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Daratumumab, pomalidomide and dexamethasone (DPG) has been shown to be efficacious in the clinical trial setting, but little is known about its role in the treatment of relapsed and refractory multiple myeloma (RRMM) in the real world setting of first relapse.

Nisha Joseph, MD and colleagues performed a retrospective chart review of patients at Emory University with RRMM who were treated with DPG. Patients had a median age of 61.9 years and 76% underwent autologous stem cell transplantation.

Median overall survival following treatment with DPG for first relapse was 41.3 months and patients who were more than 2 years from transplant had better outcomes compared to those who were within 2 years from transplant.